Michelson Diagnostics launches new improved version of VivoSight OCT scanner with Micro-Camera to aid skin cancer diagnosis
Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography (‘OCT’) technology, announces the launch of a new improved version of its innovative VivoSight OCT scanner at the European Academy of Dermatology and Venereology (EADV) Annual Meeting, 8-12 October, Amsterdam.
The VivoSight scanner probe is now equipped with a new Micro Camera that provides the user with a real-time, colour, magnified view of the skin lesion being scanned. The new Micro Camera image is shown simultaneously with the vertical and en face OCT images, making the VivoSight scanner the only dermatological clinical OCT device to provide a threefold view of the lesion. The Micro Camera view can also be stored along with the OCT image data, for later review by the clinician.
Feedback from VivoSight OCT users who have already tested the new OCT probe has been very positive:
“[The patients] will really like it. It is the first diagnostic procedure they can understand, as they can see what is going on underneath the visible lesion ” – Prof. Kurzen, Freising
“I know precisely where the scans are captured and can be assured of accurately targeting the lesion ” – Dr Algermissen, Berlin
“This additional image is an unrivalled benefit for my orientation and medical decision making ” – Dr Heckmann, Starnberg
Jon Holmes, CEO of Michelson Diagnostics, added “Our VivoSight OCT scanner is already proving popular with Dermatologists who are keen to deliver the best possible care to their non-melanoma skin cancer patients, and based on this initial feedback I am sure that the new improved probe with Micro-Camera will further accelerate the adoption of VivoSight OCT as a standard tool for the practising Dermatologist”.
The new OCT probe with Micro Camera will be demonstrated by Michelson Diagnostics at booth 98, EADV, Amsterdam. Leading VivoSight OCT users will also discuss the benefits of OCT in their practices in a ‘Meet the Experts’ session at EADV on Thursday 9 th October, Room E106, 17:00 – 18.30.
About Michelson Diagnostics and the VivoSight System
Michelson Diagnostics has developed a world-leading, patented, medical imaging technology, known as multi-beam Optical Coherence Tomography (‘OCT’), that uses an advanced laser scanner to ‘see’ into tissue with unprecedented image resolution and quality of image. Multi-beam OCT has many potential clinical applications, but we are currently focusing on dermatology.
Our vision is for our VivoSight OCT system to become the standard of care for the non-invasive diagnosis and monitoring of certain diseases and conditions that affect cutaneous and epithelial linings of the body. We currently generate revenues from our first commercial application of VivoSight, which is in the diagnosis of non-melanoma skin cancer (NMSC).
VivoSight has regulatory clearance in Europe, USA and Australia, for use by trained clinicians in their assessment of the patient’s medical condition. We have launched VivoSight in Germany where the VivoSight scan is reimbursed for patients with private healthcare insurance.
The Company, based in Orpington, Kent, was founded in 2006 and has 18 employees. It has sales offices in Germany and USA. It has been supported through funding from a syndicate of Venture Capital, corporate and private investors including Octopus, Catapult Ventures and Angel Investors.
For more information about Michelson Diagnostics, see www.michelsondiagnostics.com